SadoffJ, Le GarsM, ShukarevG, et al.Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med, 2021; 384(19):1824–1835.
4.
IchhpujaniP, ParmarUPS, DuggalS, et al.COVID-19 vaccine-associated ocular adverse effects: An overview. Vaccines (Basel), 2022; 10(11)11:1879.
5.
BadenLR, El SahlyHM, EssinkB, et al.; COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med, 2021; 384(5):403–416.
6.
PolackFP, ThomasSJ, KitchinN, et al.; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med, 2020; 383(27):2603–2615.
7.
SenM, HonavarSG, SharmaN, et al.COVID-19 and eye: A review of ophthalmic manifestations of COVID-19. Indian J Ophthalmol, 2021; 69(3):488–509.
8.
VarkeyJB, ShanthaJG, CrozierI, et al.Persistence of Ebola virus in ocular fluid during convalescence. N Engl J Med, 2015; 372(25):2423–2427.
9.
ChancellorJR, PadmanabhanSP, GreenoughTC, et al.Uveitis and systemic inflammatory markers in convalescent phase of ebola virus disease. Emerg Infect Dis, 2016; 22(2):2950–297.
NgCC, JumperJM, CunninghamETJr., Multiple evanescent white dot syndrome following influenza immunization—A multimodal imaging study. Am J Ophthalmol Case Rep, 2020; 19:100845.
12.
ShamCW, LevinsonRD. Uveitis exacerbation after varicella-zoster vaccination in an adult. Arch Ophthalmol, 2012; 130(6):793–794.
13.
Root-BernsteinR, FairweatherD. Complexities in the relationship between infection and autoimmunity. Curr Allergy Asthma Rep, 2014; 14(1):407.
14.
YadavR, BhowmickS, GoreckiP, et al.Paradoxical effect of pertussis toxin on the delayed hypersensitivity response to autoantigens in mice. PLoS One, 2010; 5(8):e11983.
15.
HoltHD, HinkleDM, FalkNS, et al.Human papilloma virus vaccine associated uveitis. Curr Drug Saf, 2014; 9(1):65–68.
NaranjoCA, BustoU, SellersEM, et al.A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther, 1981; 30(2):239–245.
19.
EdwardsIR, BiriellC. Harmonisation in pharmacovigilance. Drug Saf, 1994; 10(2):93–102.
20.
KumarA, MillerDC, SunY, et al.Risk of noninfectious uveitis after coronavirus disease 2019 vaccination in a United States claims database. Ophthalmology., 2023; 130(12):1269–1278.
21.
HwangS, KangSW, ChoiJ, et al.COVID-19 vaccination and ocular adverse events: A self-controlled case series study from the entire South Korean population. Am J Ophthalmol., 2025; 269:69–77.
22.
ShaiaJK, ShuklaP, JampolL, et al.mRNA COVID-19 vaccinations are not associated with RVO development 21 days and 12 weeks after vaccination. NPJ Vaccines., 2024; 9(1):202.
23.
KimY, HanK, KimJH. Retinal vascular occlusions after COVID-19 vaccination in south korea: A nation-wide population-based study. Ophthalmic Epidemiol., 2025; 32(4):403–411.
24.
KumarA, MillerDC, SunY, et al.Risk of recurrent noninfectious uveitis after coronavirus disease 2019 vaccination in the United States. Ophthalmol Sci, 2024; 4(4):100474.
